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ABSTRACT
Kamra, Kajal, M.S. Department of Neuroscience, Cell Biology, and Physiology, Wright
State University, 2019. Effect of Administration of Somatostatin Analogue on Blood
Pressure in Chronic Intermittent Hypoxic Rats.
The cardiorespiratory system in our bodies does not adapt to Chronic Intermittent
Hypoxia (CIH) and consequently syndromes such as sleep apnea lead to
pathophysiological conditions like Hypertension. It has been demonstrated that the
peripheral chemoreceptors underpin the development of these conditions and at present,
there are no selective drug therapies for this form of hypertension. However, evidence
suggests that peripheral chemoreflex sensitivity to CO2 & hypoxia is reduced by
Somatostatin (SST) in humans. Our preliminary in-vitro studies have demonstrated that
SST will blunt the response of the carotid body to hypoxia and decrease the baseline
activity of the carotid body. We therefore hypothesize that SST analogues given in-vivo
via osmotic minipumps will attenuate the increase in BP, thereby preventing systemic
hypertension from developing during CIH.
Adult male Sprague-Dawley rats were implanted with Osmotic minipumps containing
sterile water or SST analogue (Octreotide Acetate) and then were exposed to CIH for ≤35
days to induce hypertension. BPs were measured before, during and after IH conditioning.
Each minipump administers the drug for only 28 days. It was predicted that the animals
exposed to the SST analogue will be protected from CIH-induced hypertension.
Data showed a sudden drop in BP post-surgery in all animals tested. This hypotension may
have prevented the ability of chronic intermittent hypoxia to induce hypertension in both
experimental and control animals.

iii

Table of Contents

I.

INTRODUCTION

1

•

Anatomy and Physiology

2

•

Neurotransmitters and their Release from Carotid Body Type I Cells

7

•

Sleep Apnea, Hypertension and Intermittent Hypoxia

7

•

Somatostatin and its Analogue, Octreotide Acetate

11

•

Effects of SST and the Acute Hypoxic Response

12

II.

HYPOTHESIS AND SUMMARY

19

III.

MATERIALS AND METHODS

20

•

Animals

21

•

Standardized Blood Pressures for Rats

21

•

Surgery

29

•

Working of ALZET 2ML4 Osmotic Mini Pump

30

•

Exposure to Chronic Intermittent Hypoxia (CIH)

34

IV.
•

RESULTS

39

Standardized Blood Pressures for Rats
iv

40

V.

DISCUSSION

75

•

Important findings

77

•

Future experiments

81

•

Potential Pitfalls

81

APPENDIX

83

VI.

V11. REFERENCES

96

v

LIST OF FIGURES
Figure

Page

1. Carotid Body - Morphology and Anatomical Location………………………... 3
2. Structure, Organization of Carotid Body and its Components……………….... 5
3. Effects of SST on Carotid Sinus Nerve in-vitro………………………………..14
4. Equipment used for Blood Pressure Measurement……………………………..23
5. Schematic of BP Measurement using CODA Non-Invasive Tail-Cuff
Method………………………………………………...……………………….25
6. Schematic of Experimental Timeline…………………………………………..27
7. Schematic of Working of ALZET Osmotic Mini Pump………………………..32
8. Experimental Setup used to Condition animals to CIH………………………...35
9. CIH System Kinetics…………………………………………………………...37
10. Comparison of results of animals that did not undergo pump implantation
(surgery) with animals that did undergo surgery for pump implantation…… …42
11. Variability of tail-cuff BP measuring system with in animal and among other
animals of CNTRL + DMSO group…………………………………………….45
12. Comparison of four groups of animals studied in this experiment showing effect
of pump implantation on BP……………………………………………………48
13. Predicted effects of DMSO on sham control group BP…………………….......51
14. Experimental Effects of DMSO on BP in Sham Control Group of Animals…..54
15. Predicted Effects of DMSO on BP in Sham Control Group and CIH Exposed
Group of Animals………………………………………………………………57

vi

16. Experimental Effects of DMSO on BP in Sham Control Group and CIH
Exposed Group of Animals………………………………………………….....60
17. Predicted Effects of DMSO and SST on BP in Sham Control Group of
Animals………………………………………………………………………...63
18. Experimental Effects of DMSO and SST on BP in Sham Control Group of
Animals………………………………………………………………………...66
19. Predicted Effects of DMSO and SST on BP in CIH Exposed Group of
Animals………………………………………………………………………...69
20. Experimental Effects of DMSO and SST on BP in CIH Exposed
Group of Animals………………………………………………………………72

vii

LIST OF TABLES
Table

Page

1. Somatostatin and analogues: affinity for somatostatin receptors………………. 16

viii

ACKNOWLEDGEMENTS
Firstly, I would like to express my sincere gratitude to my advisor, Dr. Christopher
Wyatt for his continuous support during my master’s study and related research, for his
patience, motivation, and immense knowledge. His guidance helped me in all the time of
research and writing of this thesis. I could not have imagined having a better advisor and
mentor for my master’s study.
Besides my advisor, I would like to thank the rest of my thesis committee: Dr. Kathrin
Engisch and Dr. Clintoria Williams, for their insightful comments and encouragement.
My sincere thanks also go to Dr. Thomas Brown, who taught me how to use the noninvasive blood pressure measurement system and allowed me to use it for obtaining results
for my project.
I thank my fellow lab mate, Ryan Rakoczy for patiently answering all my questions, for
helping me perform survival surgeries, find research articles and for always motivating me.
Without his precious support it would not be possible to conduct this research.
Thanks to Barbara Barr for her help and guidance along the way.
I would also like to thank Mike Bottomley, Senior Statistical Consultant at Wright State
University for helping me analyze my data in every way possible.
Last but not the least, I would like to thank my family and friends for supporting me
spiritually throughout writing this thesis and with my life in general.
Please note: No editor was used in writing of this thesis.

ix

INTRODUCTION

1

Anatomy and Physiology
The carotid bodies (also known as glomus caroticum) are small peripheral sensory
organs located at the bifurcation of the common carotid artery which respond primarily to
changes in blood oxygen levels, blood carbon dioxide levels or pH (Wyatt, Evans and
Peer’s review, 2010). The carotid bodies are also viewed as polymodal organ as they can
respond to temperature and physiological fluctuations in extracellular potassium
concentrations (Kumar, 2009) to produce cardio respiratory reflexes to restore blood gas
homeostasis. The exact location of the carotid bodies is different among mammalian
species and different individuals of the same species (Lopez-Barneo, Gonzalez, 2017) but
is usually found at the bifurcation of the common carotid artery in the neck. The carotid
body possesses of glomeruli / functional unit supplied with an extensive capillary network
and connective tissue that separates glomus (T1) cells and sustentacular (T2) cells that are
known to envelope type I cells (Lopez-Barneo, Gonzalez, 2017).
T1 (Glomus) cells are small (8-15 µm) ovoidal cells whereas, T2 (sustentacular) cells
are elongated cell bodies (approximately 10 µm in diameter). Apart from their appearance,
T1 and T2 cells can also be differentiated by abundance of mitochondria and presence of
dense-core secretory vesicles in T1 cells (Lopez-Barneo, Gonzalez, 2017). The
approximated ratio of T1:T2 cells is 4:1 (Donald et al., 1981). Other than T1 and T2 cells,
CB of mammals also contain nestin⁺ cells that can produce fully grown glomus cells (Fig
1B &D) (Ortega-Saenz et al., 2013). Under hypoxia, T2 cells, which are known to be
inactive stem cells can get activated and result in formation of T1 cells or other cell types
(Pardal R et al., 2007).
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Figure 1. A) Schematic from Peers, Wyatt, & Evans (2010) showing the gross morphology
and anatomical location of the carotid body at the bifurcation of the common carotid artery
(CC). The CC diverges into the internal carotid (IC) and external carotid (EC); at the base
of this bifurcation the carotid body is normally found.
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Figure 2. Structure and organization of the carotid body (CB) adapted from Jose LopezBarneo et al., 2016. A) Photograph of the human carotid bifurcation after cleaning the
connective and fat tissue surrounding the CB (arrow) region. Scale bar, 1 cm. Male, 42 yr.
old. B) Schematic representation of the cellular components in the CB glomerulus. v, Blood
vessel. Nestin+ progenitor cells appear in green. C) Electron microscope photograph
illustrating the ultrastructure and anatomical relations of the two main cellular elements in
the mouse CB; type I cells (red) enveloped by type II cells (dark blue). The inset shows the
abundance of mitochondria and dense core secretory vesicles in type I cells. D)
Histological section of a human CB immunostained with antibodies against dopamine
decarboxylase (DDC), a glomus cell marker, and against nestin, a progenitor cell marker.
Scale bar 20 µm.
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In 1868, Pfluger announced that breathing is stimulated by hypoxia (Iturriaga, R., &
Alcayaga, J. (2004)). In between 19th and 20th centuries, a structure similar to a “ganglion”
(Iturriaga, R., & Alcayaga, J. (2004)) or “gland” (Nurse, C. A. (2010)) at bifurcation of
common carotid artery was recognized by scientists but no physiological function was
assigned to this organ until 1930. Heymans in 1930 recognized CB is a sensor of arterial
hypoxia and was awarded with a Nobel prize for his contribution in this field. Verma et al.,
1975 provided evidence that CB sensory activity disappeared when T1 cells were cryo
destroyed. This identified the T1 cells as the chemosensors.
Neurotransmitters and their Release from Carotid Body Type I Cells
To counteract changes in blood gas or pH, T1 cells are activated and are depolarized
by inhibition of K⁺ channels which results in voltage gated Ca2+ entry and the
neurotransmitter release. This then activates the afferent sensory nerve fibers of the CSN
that along with CB T1 cells form a chemical synapse. Chemoreceptor information is then
relayed to the respiratory center of brain stem to cause cardio respiratory and ventilatory
reflexes restoring normal pH levels and blood gas levels in body (Ryan and Wyatt, 2018).
CB T1 cells contain many neurotransmitters (mainly ACh, dopamine, ATP & Serotonin)
of which ACh and ATP are likely to be accountable for activation of sensory nerve fibers
(Fitzgerald et al., 1986; Zhang M et al., 2000)
Sleep Apnea, Hypertension and Intermittent Hypoxia
Sleep apnea is a clinically prevalent disorder in which breathing repeatedly stops and
starts every 15-30 seconds. The main types of sleep apneas are Central Sleep Apnea
(cessation of breathing of the respiratory rhythm) and Obstructive Sleep Apnea
7

(obstruction of the upper airway) (Nieto FJ et al., 2000; Young T et al., 1993.; Ramirez JM
et al., 2013). The obstruction of the upper airway during sleep causes termination of air
flow leading to intermittent hypoxia and affects an estimated 10 % of the population in the
US (Nanduri, J. et al., 2017).
Patients suffering from SA can develop hypertension, myocardial ischemia, stroke
and even unanticipated death (Hung et al., 1990). SA is a respiratory disease which can be
caused by several factors. Apart from abnormal upper airway or defective central CO2
chemoreceptors (Kumar, N. N. et al. 2015; Ramirez, J.-M. et al. 2013] it may also be caused
due to abnormal CB activity (Orr, J. E., Malhotra, A., & Sands, S. A. (2017); Eckert, D. J.,
White, et al. 2013); Eckert, D. J., Malhotra, A., & Jordan, A. S. (2009)).
Peng et al., 2017 proposed that CB chemoreflex activity may result in both Central
and Obstructive Sleep Apnea. They also suggested that increased CB chemoreflex begins
with carotid sinus nerve activity (CSA) which then lead to OSA by lowering the muscle
tone of the tongue which lead to blockage of the upper airway.
Patients with OSA get mainly treated with Continuous Positive Airway Pressure
(CPAP) which is known to improve oxygenation (Peng et al., 2017) but is not significantly
effective in some patients, while some find it difficult to tolerate (Peng et al., 2017). An
exaggerated CB chemosensory reflex in humans and rodents has been shown to contribute
to IH-induced hypertension (Prabhakar et al., 2015).
By chronic ablation of CB or CSN that innervates the CB, chemosensory reflex gets
disrupted, which prevents increased sympathetic nerve activity (SNA) as well as IHinduced hypertension in rats exposed to CIH (Fletcher et al., 1992; Peng et al., 2014).

8

Hypertension
“Population-based studies report an increased incidence of hypertension in OSA
patients with strong correlation between the severity of apnea and hypertension.”
(Nandhuri et al, 2017).
When exposed to IH, rodents have been shown to mimic the blood O2 saturation
profiles during OSA and exhibit hypertension. (Fletcher, 1995; Kumar et al., 2006; Peng
et al., 2006; Troncoso Brindeiro et al., 2007). The level of O2 desaturation is parallel to
elevation of systolic BP during SA which makes them hypertensive (Shephard et al., 1985).
We know that intermittent hypoxia sensitizes the CB which increases SNA. A synergistic
increase in SNA is seen when hypoxia and hypercapnia are the combined stimulus as seen
in SA (Somers et al., 1988).
Considerable evidence suggests that cardiorespiratory systems can adjust to Chronic
SH to enable to continue enough O2 delivery to tissues (Lahiri, S., Rozanov, C. &
Cherniack, N.S (2000); Bisguard, G.E. (2000). On the other hand, chronic IH causes
pathophysiological conditions like hypertension, myocardial infarcts and even stroke
(Nieto, F.J. et al.2000; Shahar, E et al. (2001)).
Apart from exposure to repetitive episodic hypoxia or stress due to normal sleep
disruption, there are various mechanisms that could contribute to chronic increase in BP in
OSA – Changes in salt and fluid balance (Krieger et al., 1991, Warley et al., 1988) and
fluctuations in intrathoracic pressure that modifies the heart and vascular system have also
been held responsible for BP changes in OSA (Bromberger-Barnea et al., 1981).
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Evidence also suggests OSA as a self-sufficient hazard for systemic hypertension. It is
known that OSA might lead to adverse cardiovascular consequences by increasing daytime
and night time sympathoadrenal activity. Evidence shows elevated levels of urinary and
catecholamine levels in OSA and increased muscle sympathetic nerve activity (SNA)
during obstructive apnea. Hypertension of OSA is maintained even during wakefulness,
thereby increasing risk of cardiovascular complications associated with hypertension (Sica
et al., 2000).
Fletcher and his colleagues demonstrated that 35 days of episodic hypoxia mimicking
the episodic hypoxemia of sleep apnea can cause a diurnal increase in mean blood pressure
of 14 mmHg (Fletcher et al., 2017). The authors also reported that when rodents were
exposed to episodic hypoxia, they exhibited an increase in Mean Arterial Blood Pressure
(MAP). This increase was found to depend upon:
a) Peripheral afferent inputs transversing the CSN
b) Level of CO2 in the hypoxic gas mixture; i.e., eucapnic hypoxia
c) An intact sympathetic NS (Fletcher et al.,1992).
Animals exposed to a similar experimental condition with a supply of room air for 30
days instead of N2 showed change in MAP.
Fletcher and his colleagues did experiments focused on the roles of renal sympathetic
nerve activity and the renin-angiotensin system in mediating the increased diurnal systemic
hypertension in their model of IH (Fletcher et al., 2017). In their study, systemic
hypertension was shown to be associated with activation of renin-angiotensin system as
indicated by up-regulation of renin during the non-hypoxic periods of their protocol as well
as the finding that blockade of the angiotensin II type I receptor eliminated the increase of
10

arterial blood pressure and renal nerve activity. These results provide substantial support
for the role of the sympathetic system in the blood pressure response to long-term
intermittent hypoxia (Fletcher et al., 1999). The key role of the sympathetic system was
also supported by finding of A.L. Sica in anesthetized preparations that the amplitude of
preganglionic SNA during hypoxia, hypercapnic, and asphyxic stimulation was
significantly greater in animals previously exposed to CIH compared to control animals.
The findings prove how chronic exposure to IH is linked with increase in activation of
brain stem and some regions of neuro axis that are responsible in shaping the sympathetic
outflow (Sica et al., 2000).
There is an increase in both SNA and minute ventilation from peripheral
chemoreceptor stimulation in response to a hypoxic stress. It has also been shown that
surgical removal of CB blocks sympathetic activation and prevents hypertension on IH
subjected rats (Fletcher et al., 1992; Peng et al., 2003).
Somatostatin and its Analogue, Octreotide Acetate
After the discovery of SST in 1973 (Brazeau et al., 1973), a new approach to the
treatment of conditions associated with endocrine hypersecretion, such as acromegaly,
Cushing’s disease, and symptoms of metastatic neuroendocrine tumors (NET), was
initiated (Weckbecker et al., 2002).
SST was first described in the hypothalamus but SST producing cells are also found in
central and peripheral nervous system, pancreas, gut, thyroid, adrenal, spleen, liver,
kidneys and prostate. SST is also produced by immune cells. [Patel YC et al.,1999]. SST
comes in 2 bioactive forms- SST 14 and SST 28 which are synthesized from
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preprosomatostatin, a large precursor molecule SST is produced in different quantities by
different cells and, at least in the rat, the gut accounts for 65% of total body SST-like
immunoactivity, the brain for 25%, the pancreas for 5% and the remaining organs, for 5%
[Patel YC et al.,1978]. SST is known to acts as a neurotransmitter and as an autocrine,
paracrine or endocrine regulator. Numerous physiological functions including modulation
of neurotransmission, cell secretion and proliferation, smooth muscle cell contractility,
intestinal motility, absorption of nutrients and immune cell functions are controlled by SST
(Patel YC et al., 1999).

Effects of Somatostatin and the Acute Hypoxic Response
Somatostatin has been localized with in nerve fibers innervating the arterial
chemoreceptors (Kummer et al., 1989, 1990 and Kameda 1989). In a small pilot study
where Somatostatin Acetate dissolved in saline to achieve a concentration of 0.05 mg/ml
was infused into a forearm vein in human subjects at the rate of 10 ml/h and lasted 64
minutes (Robbins et al., 1999). Their breathing, heart rate and blood pressures were
recorded throughout the experiment. As a result, 5 out of 9 subjects reported side-affects
like nausea, head ache and stomach-ache from SST administration. No changes in heart
rate or blood pressures were found but SST attenuated the fast (peripheral) component of
the ventilatory response to hypercapnia under hypoxia but had no effects on the slow
(central) component of the ventilatory response to hypercapnia. It also depressed the
ventilatory response to hypoxia (AVHR).
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In 1995, e Silva & Lewis showed that somatostatin also inhibited whole cell calcium
current peaks by 24% recorded from chemoreceptor Type I cells from the rat carotid body.
“In humans, infusions of somatostatin greatly reduce the ventilatory sensitivity to hypoxia
(Maxwell et al., 1986 a, b; Filux et al., 1988). All this suggests that the most likely site of
action of Somatostatin on the hypoxic ventilatory response is at the carotid body.”
(Robbins et al., 1999).
Our collaborators, Dr. Richard Wilson and his students at University of Calgary,
Canada carried out an in-vitro experiment where they took out rat carotid bodies still intact
with the carotid sinus nerve (CSN) and perfused it with hypoxic perfusate. They saw an
increase in the firing frequency along the sinus nerve. They then perfused it with SST
(1µM) and saw a significant reduction in the baseline firing of the CSN activity. Upon
washing the SST away, the CSN activity was restored to the normal levels (Figure 3).
(UNPUBLISHED WORK)
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Figure 3. Effect of SST on carotid sinus nerve in-vitro (Unpublished data from Dr. Richard
Wilson’s laboratory at University of Calgary, Canada): Upper figure- Y axis shows the
change in CSN activity and the X axis shows the time in seconds. CSN activity increased
when Carotid bodies (attached to CSN) were perfused with hypoxic perfusate (Hx) and the
baseline CSN decreases when perfused with SST (1µM). The lower figure represents the
mean data of this experiment in the form of bar graphs.
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Table 1. Somatostatin and analogues: affinity for somatostatin receptors (Adapted from H.
Reynaert et al., 2003).

SST and its analogues work through six G-Protein coupled receptors (SST1 through
5) including two splice variants, SST 2A and SST 2B (Goodchild AK et al., 1982; Padley
JR et al., 2003) that control the activity of ion channels (Ca2+, K+, Na+ and Cl-) and
enzymes (Adenyl Cyclase, Phospholipase C, Phospholipase A2, Phosphoinositide 3Kinase and Guanylate Cyclase) culpable for the synthesis or degradation of intracellular
second messenger (CAMP, inositol 1,4,5-triphosphate, diacylglycerol and CGMP). All the
SSTRs are coupled negatively to adenylate cyclase, activate phosphotyrosine phosphates,
and modulate MAP kinase, whereas subtype-specific actions are also evident (Goodchild
AK et al., 1982; Padley JR et al., 2003).
There is evidence that SSTR and SST containing cell bodies and terminals are
present in the ventral medulla where the respiratory centers are located (Peter G.R. Burke
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et al., 2008). Not much is known about their functional roles, except that microinjection of
SST evokes apnea (Peter G.R. Burke et al., 2008).
Peter G.R. Burke found that when SST is bilaterally injected at Rostral Ventrolateral
Medulla (RVLM) pressor sites, it evokes bradycardia, a large depressor response and
robust sympathoinhibition. They also found that activation of SST2A receptors in RVLM,
located on only approximately 35% of pre-sympathetic neurons containing TH and/or PPe,
evoked intense sympathetically mediated hypotension and bradycardia.
SST is known to attenuate cellular proliferation by a direct effect on cellular division
(Payan D et al., 1984), by reduction of the release of both Growth hormone (GH) (Moreau
et al., 1987) and Insulin Growth Factor (IGF) (Grant MB et al.,1994) and reduction of Ca2+
currents in neuron (Wang H et al., 1990). Tjen-A-Looi S in 1992 provided evidence that
chronic infusion of SST-14 neurons (20ug/rat/h) reduces pulmonary arterial pressure in
chronically hypoxic rats.
SST analogues are efficiently linked to the human SSTR selectivity profile, with a
synergistic SSTR2 and SSTR5 binding appearing critical (Tolis et al., 2006). One such
synthetic analogue of SST, Octreotide (an eight amino acid cyclic peptide analogue) has
been in clinical trials since 1984. It has more protracted pharmacological actions than SST
and primarily bind with high affinity to human SSTR2 but show reduced or no binding to
SSTR 1, 3, 4 and 5 (Table 1) (Tolis et al., 2006). In many studies, Octreotide has been used
to treat acromegaly and esophageal variceal hemorrhage in humans mainly as bolus
injections of 50µg followed by 25-50µg/h (Reynaert et al., 2003). Some also use Long
Acting Release (LAR) Octreotide by deep subcutaneous depot injections to administer a
dose of 20mg-40mg/month (Colao et al., 2009; Tolis et al., 2006).
17

Patients with acromegaly tend to develop hypertension due to multifactorial
mechanisms. In a published study by George Toils and others in 2006, when treated with
Octreotide for six months, there was a decrease in systolic blood pressure in patients with
left ventricular hypertrophy.
“SST analogues (SSTA) have a beneficial effect on BP (G. Minniti et al., 2001; A.
Coloa et al., 2001), significantly improve heart rate and cardiac function, reduce left
ventricular mass, improve systolic and diastolic function, and exercise training (G. Minniti
et al., 2001; A. Coloa et al., 2000; P. Maison et al., 2007), improve diastolic filling (L. De
Marinis et al., 2008), and may even reduce the rate of arrythmias (A. Calao et al., 2012;
G. Lombardi et al., 2002), without a significant influence over heart valve disease (A.A.
van der Klaauw et al., 2006; A.A. van der Klaauw et al., 2008).”
In another study, eleven patients (seven females and four males) received Octreotide
(100-200µg), three times daily, subcutaneously over a 6-month period. Overall, systolic
and diastolic mean pressures, heart rate and electrocardiograms did not change
significantly throughout the investigational period (Bartolomeo Merola et al., 1993). There
is some evidence that SST can modify the renin-angiotensin system in a manner that could
lower BP independent of any effect on the endocrine pancreas (Izumi Y et al., 1980).
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Hypothesis and Summary
We hypothesized that SST analogues given in-vivo will attenuate systemic
hypertension from developing during intermittent hypoxia by attenuating an increase in
BP.
To test this hypothesis, we used 32 male Sprague Dawley rats – control rats (n=16)
and experimental rats (n=16). The experimental rats were exposed to Chronic Intermittent
Hypoxia (4-5% O2, 15 events/hour, 8 hours/day for ≤35 days) to induce hypertension. The
control rats were exposed to room air throughout the experiment. ALZET 2ml osmotic
minipumps were surgically implanted subcutaneously to administer SST analogue,
Octreotide Acetate in rats. Blood pressure was recorded before and after the surgery and
weekly thereafter by using CODA non-invasive BP system.
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MATERIALS AND METHODS

20

Animals
38 adult male Sprague Dawley rats (170g) were used in this experiment (Envigo,
Indianapolis, IN) They were randomly subcategorized into control (n=19) and
experimental (n=19) groups. They were weighed separately at the time of arrival and each
week thereafter. They were all fed standard rat chow (Teklad 8640 from Envigo) and water.
Standardized Blood Pressures for Rats
From day 4 to day 5, i.e. after 3 days of rest and acclimation to the room, the rats
were acclimated to the CODA non-invasive blood pressure system (a tail-cuff method,
Kent Scientific Corporation) for 20 cycles per rat between 8:30 am to 11am only. On day
6, the day before surgery, each animal was weighed, and baseline BPs were recorded using
the CODA noninvasive BP system. BPs were also recorded two days after surgery (Postop BP) (day 9), on first (day 16), second (day 23), third (day 30) and fourth (day 37) week
of exposure to CIH.
After placing the rats in the CODA rat holders/tubes (Figure 4) (made sure they were
comfortable and not squished), the holders were placed on top of a dry paper towel on the
warming platform/tray (to the desired temperature, 34⁰C). The O-cuff and VPR-cuff were
gently placed up the tail until resistance was felt. A slight gap, not more than 2 mm was
maintained between the two cuffs. These tail cuffs were attached to the CODA machine
which was attached to a computer (Figure 5) where all the recordings were recorded.
For at least 10 minutes, the rats could get acclimated and the tail temperature to rise
to 34⁰C. To achieve adequate tail temperatures quickly, a warm water filled glove was
placed on the rat’s tail (avoiding tubing) and a warm pad (Kent Scientific) over the restraint
21

for rats. Water-glove and heating pad were placed and removed as necessary to maintain
proper tail temperature.
Once the rats were calm & up to temperature, we ran the cycles. Each rat ran 1 time
with a total of 5 acclimation and 15 regular cycles. The data was exported and saved by
date, group and animal number onto a MS Excel spreadsheet for further statistics. No CIH
exposure on the day of BP measurement was done.
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Figure 4. A) Image of Rat Holders in-use. (Adapted from Kent Scientific Corporation
Websitehttps://www.kentscientific.com/products/productView.asp?productID=6376&Mouse_Rat
=Holders&products=Nose+Cone+Animal+Holders+with+Stand) B) Image of warming
pads used to keep the rat restrainers warm. (Adapted from Kent Scientific Corporation
websitehttps://www.kentscientific.com/products/productView.asp?productID=6234&Mouse_Rat
=Warming+Pads&products=Far+Infrared+Warming+Pad)
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A)

B)
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Figure 5. Schematic of Measurement of Blood Pressure using CODA non-invasive tail
cuff method.
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Figure 6. Schematic of experimental timeline used in this research project. Animals were
acclimated to the experimental room for 3 days. On day 7, ALZET 2ml4 osmotic
minipumps containing either DMSO or drug were surgically implanted subcutaneously in
the back of the animals and blood pressure was recorded before and after the surgery and
weekly thereafter for 4 weeks.
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Surgery
On day 7, we surgically implanted ALZET 2ml4 osmotic mini pumps (Model 2ML4;
Alzet Corp., Palo Alto, CA) that were filled with 8.5µg/ml/Kg of Octreotide Acetate
(Somatostatin Analogue from Fisher Scientific)/Sterilized Water for the experimental/
control animals respectively (The standard protocol uses 10µg/ml/Kg of Octreotide per rat
(Schmid et al., 2012)). Each animal weighed different at the time of surgery, so different
concentrations of drug were calculated accordingly.
On each experimental day, eight male Sprague Dawley rats (45-60 days old), one at
a time, were exposed to 2-5% isoflurane and 100% oxygen at a flowrate of 0.5L/min in an
anesthesia induction chamber. Once the animal was unconscious, it was transferred to a
nose cone underneath a dissecting microscope where it was exposed to the same anesthetic
gas and flow rate as in induction chamber. Reaching the proper anesthetic plane was
ensured by testing the animals’ withdrawal reflex using a foot and tail pinch. Once the rat
had no response to the pinch, its limbs were taped down to keep it stationary, and the pump
implantation surgery was carried out.
Each implantation started with the shaving of the incision area with an electric razor
and cleansing with 70% Ethanol; followed by scrubbing the area thrice with betadine using
cotton applicators (Fisher Scientific) and cleansing with 2” x 2” cotton gauze pad (Fisher
Scientific) and then again with 70% ethanol & gauze pad.
Using a surgical scalpel (World Precision Instruments, Scalpel Handle #3, German
500236-G), a small mid-scapular incision was made along the vertebral column to expose
subcutaneous fascia. Then by using a bigger surgical scissor and a needle holder (Fine
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Science Tools, Crile-Wood, 12503-15), this initial incision was enlarged in order to make
a pouch/pocket subcutaneously to hold the sterile osmotic mini pump. The sterilized
osmotic mini pump was then placed longitudinally (parallel to the spinal cord): flow
moderator facing posteriorly (facing towards the tail) within the subcutaneous cavity. Any
excessive bleeding was wiped off with a 2” x 2” gauze. To close the incision site, VISORB
(absorbable) sutures were used (CP Medical, Coated Visorb, violet braided, Size: 4-0,
Needle:C-3, Shape: 3/8 Circle). Starting with a surgeon’s knot on the posterior end of the
incision and followed by continuous stitch on the way up to the top of the incision and then
closing it up with another surgeon’s knot. The incision area was again lightly scrubbed
with betadine to kill any bacteria or germs in that area to prevent infection. Immediately
after the completion of each survival surgery, the rats were given a 0.1ml/100g dose of
Carprofen as a pain reliever.
Working of ALZET 2ML4 Osmotic Mini Pump
Osmotic pump is made up of an outer semi permeable membrane, middle osmotic
layer and an inner impermeable drug reservoir of 2 ml (2000 µl). The pump is designed to
administer the drug at a pump rate of 2.5µl/h continuously for 28 days when filled and
implanted. The fill volume of the pump reservoir should be over 90% of the mean fill
volume (i.e. equal to 2000 µl) indicated in the lot specifications at the top of the instructions
sheet in the ALZET 2ML4 osmotic mini pump box.
To avoid puncturing the pump reservoir, the filling needle provided with the pumps
was only used. The pump was then capped with the flow moderator.
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Once implanted, body fluid from the animal is taken up by the outermost semipermeable
membrane, followed by the middle osmotic layer of the pump causing it to swell and thus
shrinking the innermost reservoir volume and causing the drug to be delivered out of the
pump into the animal’s body via flow moderator.
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Figure 7. Schematic of ALZET osmotic minipump.
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Exposure to Chronic Intermittent Hypoxia (CIH)
Freely mobile animals housed in a feeding cage (11 x 11.5 x 17 inch), two cages per
session with up to four animals per cage were placed in hermetically sealed chronic
intermittent hypoxic chambers (Figure 8) (15 x 20 x 21 inch; COY). With the help of gas
mixer, the hypoxic chamber was flushed with 100% Nitrogen for 36 seconds to reduce the
ambient fractional concentration of Oxygen (FIO2) to 5% for 1 sec. This was followed by
infusion of Oxygen allowing FIO2 = 21%. In the meanwhile, when Nitrogen was being
supplied to the hypoxic chamber, normoxic chamber was supplied with compressed air to
simulate the same noise and air disturbance. The cycle was repeated 15 times/hour for
8hours/day for ≤ 35 days.
This entire set of experiment was repeated with four different times, each time with
a new set of animals (therefore, total N=32). Paired student’s T-Test was run for each group
of animals and values ≤ 0.05 were considered statistically significant. Michael Bottomley,
Statistical Programmer Analyst at Wright State University did a separate analysis for the
data obtained through this experiment. For each of the three response variables (SBP, DBP
and MAP), a repeated measures mixed effects ANOVA with a random effect for rat ID
was run. The repeated measures aspect takes the correlation between time points for each
rat into effect and the random effect factors in the correlation for the 5 measurements on
each rat at each of the time points. A level of significance of alpha = 0.05 was used for
each model. (See Appendix)
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Figure 8. Experimental setup used to condition animals to Chronic Intermittent Hypoxia.
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Figure 9. Chronic intermittent hypoxia system kinetics. T1: ramp down to hypoxia, T2:
hypoxia soak, T3: ramp up to normoxia, T4: normoxia soak
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RESULTS
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Standardized Blood Pressures for Rats
This study is done to test the hypothesis that a sustained allocation of SST or SST
analogue will attenuate BP in chronic intermittent hypoxic rats. Thirty-two male Sprague
Dawley rats separated into two equal groups- Control (CNTRL) and Experimental (CIH)
(n=18), were further divided into four equal sub-groups – Control + No Drug (CNTRL +
DMSO), Control + Drug (CNTRL + SST), Experimental + No Drug (CIH + DMSO) and
Experimental + Drug (CIH + SST). After three to four days of acclimation to the room,
baseline blood pressures (Systolic, Diastolic and Mean arterial) were measured one day
before the surgery (PRE) and then on the third day after surgery (POST) and then weekly
thereafter for up to four weeks (W1→ W4).
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Figure 10 shows change in SBP from week 3 to week 4 in all 6 groups of animals. On Y
axis is the systolic BP and on X axis are CNTRL + DMSO, CNTRL + SST, CIH + DMSO,
CIH + SST, CNTRL group without surgery and CIH group without surgery. Error bars are
the standard errors of the mean calculated as standard deviation/square root (n-1). A
significant drop in SBP is seen from week 3 to week 4 in CNTRL + SST group, which
opposes our hypothesis as this group was not expected to show any significant change in
BP. A significant decrease (p≤0.05) (student’s t-test) in SBP is seen from week 3 to week

4 in CIH + DMSO group of animals. This group also opposes our hypothesis. CIH + SST
group of animals do not show a significant change in BP. This group was expected to show
a significant decrease in BP at the end of week 4 and therefore failed our hypothesis.
The last two groups depict results as expected on exposure to normoxia and CIH (but
without surgery). A significant increase in BP is seen in animals that were exposed to CIH
in comparison to animals that were not. This ensures that the CIH system works effectively.
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Figure 10. Comparison of results of animals that did not undergo pump implantation
(surgery) with animals that did undergo surgery for pump implantation.
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Figure 11 shows the variability of the method measuring BP by tail cuff plethysmography.
Y axis is the Systolic BP (mmHg) and on the X axis are 6 random animals from CNTRL +
DMSO group. For each animal 5 SBP recordings are taken into consideration and
variability with in each animal as well as between animals is depicted in the following
figure.
For animal 1, four out of five recordings fall in the range of 165mmHg -190mmHg. For
animal 2, SBP recordings are in the range of 155mmHg-175mmHg. Animal 3 SBP is the
range of 177mmHg-198mmHg. Animal 4 is in the range of 154mmHg-165mmHg. Animal
5 is in the range of 190mmHg-215mmHg. Animal 6 shows most variation with in itself
with 3 readings being in the range of 129mmHg-145mmHg and other two in the range of
173mmHg-183mmHg.
All these SBP ranges are higher than the normal SBP range which is 120-140mmHg.
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Figure 11. Variability of tail-cuff BP measuring system with in animal and among other
animals of CNTRL + DMSO group.
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Figure 12 shows changes in SBP throughout the experimental timeline in CNTRL + SST
(n=8), CNTRL + DMSO (n=8), CIH + SST (n=8) and CIH + DMSO (n=8) group of
animals. Y axis is the SBP and on the X axis is different timepoints at which BP was
measured- pre-surgery, post-surgery, week 1, week 2, week 3 and week 4. Error bars are
the standard error of mean calculated as standard deviation/square root(n-1).
For CNTRL + DMSO group, no significant difference (p>0.05) is seen from post-surgery
to week 4 hence, supports our hypothesis. In CNTRL + SST group a significant increase is
seen from post-surgery to Week 4 BP. In CIH + DMSO group, a significant increase (p≤

0.05) is seen from pre-surgery to post-surgery in systolic blood pressure, no significant
change in BP is seen from pre-surgery to post-surgery BP for CIH + SST group of animals.
A significant increase (p≤0.05) is seen from post-surgery to week 4 in DMSO containing

CIH exposed group, but no significant difference is seen in case of drug containing CIH
exposed group of animals. CIH + DMSO group of animals oppose our hypothesis. They
should have had an increase in BP in comparison to CIH + SST group. CIH + SST also
failed the hypothesis as it shows an increase in BP. All groups showed a drop in BP at week
1. This could be because some other mechanism in the body tries to bring the BP to the
normal range to maintain homeostasis.
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Figure 12. Comparison of four groups of animals studied in this experiment showing that
surgery/implantation of osmotic minipump causes a consistent, but transient, drop in BP.
A) CNTRL + DMSO, B) CNTRL + SST, C) CIH + DMSO and D) CIH + SST
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Figure 13 shows the predicted effects of DMSO in sham control group (n=4) on systolic,
diastolic and mean arterial BP. Figure A shows systolic BP (mmHg) on Y axis and presurgery BP, post-surgery BP, W1 BP, W2 BP, W3 BP and W4 BP on X axis. Same axis is
followed for figure B Diastolic BP and figure C- MAP. Error bars are standard error of the
mean calculated as standard deviation/ √(n).
No changes in BP from pre-surgery to post-surgery in systolic, diastolic and MAP are
expected. Also, no significant difference in BP from post-surgery (baseline) to week 4.
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Figure 13. Predicted effects of DMSO in sham control group BP. A) systolic BP, B)
diastolic BP and C) mean arterial blood pressure.
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Figure 14 shows the experimental effects of DMSO in sham control group (n=4) on
systolic, diastolic and mean arterial BP. Figure A shows systolic BP (mmHg) on Y axis
and pre-surgery BP, post-surgery BP, W1 BP, W2 BP, W3 BP and W4 BP on X axis. Same
axis is followed for figure B Diastolic BP and figure C- MAP. Error bars are standard error
of the mean calculated as standard deviation/ √(n).
Systolic BP has a p>0.05 hence is not significant across the experimental timeline. A
significant decrease (p≤0.05) in BP from pre-surgery to post-surgery is seen in MAP, but

not in systolic and diastolic BP. No significant difference (p>0.05) in BP from post-surgery
to week 4 in systolic, diastolic and MAP is seen.
A drop in BP (systolic, diastolic and MAP) is seen at week 1. Systolic and diastolic BP
recordings support our hypothesis as no final change in BP should be seen in control
animals that were exposed to normoxia but MAP recordings oppose our hypothesis.
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Figure 14. Experimental effects of DMSO in sham control group BP. A) systolic BP, B)
diastolic BP and C) mean arterial blood pressure.
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Figure 15 shows Predicted effects of DMSO on systolic (n=8) (figure 15A), diastolic (n=8)
(figure 15B) and MAP (n=8) (figure 15C) recordings of sham control group and CIH
exposed group of animals. Figure A shows systolic BP (mmHg) on Y axis and pre-surgery
BP, post-surgery BP, W1 BP, W2 BP, W3 BP and W4 BP on X axis. Same axis is followed
for figure B Diastolic BP and figure C- MAP. Error bars are standard error of the mean
calculated as standard deviation/ √(n).
No significant difference is predicted from pre-surgery to post-surgery in systolic, diastolic
and MAP for both sham control group and CIH exposed group. Also, no significant
difference is predicted in systolic, diastolic and MAP from post-surgery (baseline) to week
4 for sham control group. A significant increase (p≤0.001) from post-surgery to week 4 is
predicted in systolic, diastolic and MAP for CIH exposed group of animals in comparison
to the controls.
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Figure 15. Predicted effects of DMSO in sham control group and CIH exposed group of
animals’ BP. A) Systolic BP, B) Diastolic BP and C) MAP.
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Figure 16 shows the experimental effects of DMSO in sham control group (n=4) and CIH
exposed group of animals (n=4) on systolic, diastolic and MAP. Figure A shows systolic
BP (mmHg) on Y axis and pre-surgery BP, post-surgery BP, W1 BP, W2 BP, W3 BP and
W4 BP on X axis. Same axis is followed for figure B Diastolic BP and figure C- MAP.
Error bars are standard error of the mean calculated as standard deviation/ √(n).
No significant difference (p>0.05) is seen in systolic, diastolic and MAP for CIH exposed
group over time. A significant decrease from post-surgery to week 4 in systolic, diastolic
and MAP for CIH exposed group of animals is seen.
CIH + DMSO group opposes our hypothesis. They should have had an increase in BP in
comparison to CNTRL + DMSO group as they were exposed to CIH and not treated with
SST. CNTRL + DMSO group (systolic and diastolic) support our hypothesis.
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Figure 16. Experimental effects of DMSO in sham control group and CIH exposed group
of animals’ BP. A) Systolic BP, B) Diastolic BP and C) MAP.
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Figure 17 shows Predicted effects of DMSO (n=4) and drug (SST) (n=4) on systolic
(n=8, 𝑥̅ = 170.04 𝑣𝑠 174.3) (figure 17A), diastolic (n=8, 𝑥̅ =133.33 vs 134.33) (figure
17B) and MAP (n=8, 𝑥̅ =154.75 vs 154.75) (figure17C) in sham (normoxia) control group
of animals. Figure A shows systolic BP (mmHg) on Y axis and pre-surgery BP, postsurgery BP, W1 BP, W2 BP, W3 BP and W4 BP on X axis. Same axis is followed for
figure B Diastolic BP and figure C- MAP. Error bars are standard error of the mean
calculated as standard deviation/ √(n). No significant difference (p>0.05) from pre-surgery
to post-surgery or from post-surgery (baseline) to week for systolic, diastolic and MAP for
both DMSO and drug containing sham control group.
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Figure 17. Predicted effects of DMSO and drug (SST) in sham control group of animals.
A) Systolic BP, B) Diastolic BP and C) MAP.
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Figure 18 shows the experimental effects of DMSO (n=4) and drug (SST) (n=4) on systolic
(n=8), diastolic (n=8) and mean arterial blood pressure (n=8). Figure A shows systolic BP
(mmHg) on Y axis and pre-surgery BP, post-surgery BP, W1 BP, W2 BP, W3 BP and W4
BP on X axis. Same axis is followed for figure B Diastolic BP and figure C- MAP. Error
bars are standard error of the mean calculated as standard deviation/ √(n).
A significant increase (p≤0.05) is seen from pre-surgery to post-surgery in MAP for
CNTRL + DMSO but none (p>0.05) is seen from pre-surgery to post-surgery for systolic,
diastolic and MAP for drug containing sham control group. No significant difference seen
from pre-surgery baseline to week 4 in systolic, diastolic and MAP for DMSO containing
sham control group. No significant difference seen from post-surgery to week 4 in systolic,
but a significant difference (p≤0.05) seen in diastolic and MAP for drug containing sham
control group. CNTRL + DRUG group opposes our hypothesis. They were expected to not
show any change in BP as they were exposed to normoxia. Whereas, CNTRL + DMSO
(systolic and diastolic BP) support our hypothesis.
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Figure 18. Experimental effects of DMSO and drug (SST) in sham control group of
animals. A) Systolic BP, B) Diastolic BP and C) MAP.
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Figure 19 shows predicted effects of DMSO (n=4) and drug (SST) (n=4) on systolic
(n=8, 𝑥̅ =175.7 vs 178.36) (figure 17A), diastolic (n=8, 𝑥̅ =135.73 vs 138.4) (figure 17B)
and MAP (n=8, 𝑥̅ =157.61 vs 162.28) (figure17C) in CIH exposed group of animals.
Figure A shows systolic BP (mmHg) on Y axis and pre-surgery BP, post-surgery BP, W1
BP, W2 BP, W3 BP and W4 BP on X axis. Same axis is followed for figure B Diastolic
BP and figure C- MAP. Error bars are standard error of the mean calculated as standard
deviation/ √(n). No significant difference (p>0.05) from pre-surgery to post-surgery in
systolic, diastolic and MAP for both DMSO and drug containing CIH exposed groups. A
significant increase (p≤0.001) is predicted from post-surgery (baseline) to week 4 in
systolic, diastolic and MAP for DMSO containing CIH exposed group. No significant
difference (p>0.05) from post-surgery (baseline) to week 4 in systolic, diastolic and MAP
for drug containing CIH exposed group of animals.
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Figure 19. Predicted effects of DMSO and drug (SST) in CIH exposed group of animals.
A) Systolic BP, B) Diastolic BP and C) MAP.
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Figure 20 shows the experimental effects of DMSO (n=4) and drug (SST) (n=4) in CIH
exposed group of animals, both treated (with SST) and not treated (with DMSO) on
systolic, diastolic and mean arterial blood pressure. Figure A shows systolic BP (mmHg)
on Y axis and pre-surgery BP, post-surgery BP, W1 BP, W2 BP, W3 BP and W4 BP on X
axis. Same axis is followed for figure B Diastolic BP and figure C- MAP. Error bars are
standard error of the mean calculated as standard deviation/ √(n).
A significant increase from pre-surgery to post-surgery in systolic (p≤0.01), diastolic
(p≤0.001) and MAP (p≤0.001) for DMSO containing CIH exposed group is seen. No
significant difference (p>0.05) is seen from pre-surgery in systolic, diastolic and MAP seen
for drug containing CIH exposed group of animals. A significant decrease seen in systolic
(p≤0.0001), diastolic (p≤0.01) and MAP (p≤0.01) from post-surgery (baseline) to week 4
in DMSO containing CIH exposed group but no significant difference (p>0.05) seen in
case of drug containing CIH exposed group of animals.
CIH + DMSO group of animals oppose our hypothesis. They should have had an increase
in BP in comparison to CIH + SST group. CIH + SST also failed the hypothesis as it
showed a significant increase in BP.
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Figure 20. Experimental effects of DMSO and drug (SST) in CIH exposed group of
animals. A) Systolic BP, B) Diastolic BP and C) MAP.
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The only rats to show a significant increase from W1 to W2 were the CIH rats on the SST,
which is the opposite of the desired effect. This group did show a descriptive decrease
from W2 to W3 and from W3 to W4, although not a statistically significant decrease. The
control rats on the SST showed significant increases from Pre to W3, Post to W3, W1 to
W3, and W2 to W3.
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DISCUSSION
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Sleep apnea is a clinically prevalent disorder in which breathing repeatedly stops
and starts every 15-30 seconds (Nieto FJ et al., 2000; Young T et al., 1993.; Ramirez JM
et al., 2013).
The obstruction of the upper airway during sleep causes termination of air flow
leading to intermittent hypoxia and affects an estimated 10 % of the population in the US
(Nanduri et al., 2017). Patients suffering from SA showcase emanations involving
hypertension, myocardial ischemia, stroke and even unanticipated death (Sica et al., 2000).
Patients with OSA get mainly treated with CPAP which is known to improve oxygenation
(Peng et al., 2017) but is not significantly effective in some patients, while some find it
difficult to tolerate (Peng et al., 2017). An exaggerated CB chemosensory reflex in humans
and rodents has been shown to contribute to IH-induced hypertension (Prabhakar et al.,
2015).
When exposed to IH, rodents have shown to mimic the blood O2 saturation profiles
during OSA and exhibit hypertension (Fletcher et al., 1995; Kumar et al., 2006; Peng et
al., 2006; Troncoso Brindeiro et al., 2007). The level of O2 desaturation is parallel to
elevation of systolic BP during SA (Shepard et al., 1985).
Based on all these findings and the findings by Dr. Wilson, we hypothesized that SST
analogues given in-vitro will attenuate the response of carotid body to intermittent hypoxia
and then prevent carotid body sensitization, thus preventing systemic hypertension from
developing during intermittent hypoxia.
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Important Findings
CONTROL + DMSO: Since the animals were not exposed to CIH, they should not be
hypertensive. Also, as they were not given any treatment drug (SST), we should see no
change in BP from W1 to W4. Although, we might expect to see some changes in BP postsurgery.
The observed drop in BP could be due to the use of anesthesia, hypovolemic shock,
septic shock. A rise in BP can be a result of pain or stress. As per the actual data collected,
interestingly, we see a significant drop in BP at W1 in all animals. In all animals that had
surgery, all treated (Octreotide) and control groups, show a significant hypotension
following surgery. We also see a significant drop in MAP in CONTROL + DMSO group
of rats from Pre to Post (which could be due to septic shock) and an overall drop in BP
from Pre-surgery to W4. The sudden drop in BP at W1 could have possibly not allowed
the W4 BP to rise back to its normal BP levels. But we see no significant change in BP
from post-surgery to W4 in Systolic, Diastolic and MAP. Fletcher et al., 1992 performed a
similar experiment with almost same protocol and showed that the animals become
hypertensive. BP was indirectly measured in unconscious rats using an inflatable tail-cuff
and photoelectric sensor. It was different from our experiment as they did not perform any
surgeries or implant minipumps.
CIH + DMSO: Animals should become hypertensive which means their BP should
increase. Also, they were given the vehicle- DMSO, instead of the drug, SST, therefore
we expected to see an increase in BP. Prabhakar et al., 2017 provided evidence that unlike
ST (short term)-IH (10 days exposure to CIH), LT (long term)-IH (30 days) leads to
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irreversible changes in elevated BP and irregular breathing and these are associated with
persistent activation of the CB chemosensory reflex.
For this group of animals, we saw a significant increase in BP from pre-surgery to
post-surgery which I speculate can be a result of pain or distress in animals due to surgery.
A constant drop in BP at W1 is seen in this group of rats as well. We also see a drop in BP
from post-surgery to W4 which is exact opposite of what we expected. Surprisingly, from
pre-surgery to W4, there is no significant difference in systolic, diastolic or MAP. One
could think that the CIH system may have been ineffective but that cannot be true. The
effectiveness of the system was ensured when we performed CIH controls with no surgery
before proceeding with the actual experiment. Figure 18 shows experimental results (n=6)
for in-vivo studies of animals that did not undergo surgery. Here, we see a significant
increase in systolic, diastolic and MAP of CIH control rats from W3 to W4.
CONTROL + DRUG: This is the group of rats that were surgically implanted with pumps
containing SST analogue but were not exposed to CIH. We expected them to not get
hypertensive, therefore no increase in BP and therefore the drug should not work. They
should behave like the controls with no drug. While analyzing the actual data, we saw that
the drug had effects opposite to what we expected. There was a significant rise in BP from
post-surgery to W4. It should have been the opposite (Figure 15). MAP shows a significant
change in pre and post-surgery baseline and no significant change from post-surgery to W4
BP measurements.
Final average group B [CNTRL + SST] (in gray) shows no significant change in BP from
post-surgery to W4. For diastolic and MAP, there is a significant change in BP from postsurgery to W4.
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As the time frame of the experiment was limited by the lifespan of the pump. It is also
strange that the control rats on SST showed significant increases from Pre to W3, Post to
W3, W1 to W3 and W2 to W3. This group would have the least likely to show any increase
in SBP of the three groups if the SST is effective. (see appendix).
CIH + DRUG: We expect the animals to become hypertensive as they were exposed to
CIH, which is why their BPs should increase since they were treated with drug-SST.
Hoffman et al., 1989 demonstrated an increase in BP in animals with osmotic pumps
containing SST analogues (dissolved in 0.9% saline) at a rate of 10µg/kg/h for 7 days in
comparison to the controls with 0.9% NaCl in their pumps.
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Systolic BP for adult male Sprague Dawley rats should be in the range of 120-130mmHg
but our rats’ systolic BP was in the range of 160-170mmHg which means our rats were
already hypertensive. They could have been hypertensive because of our approach to BP
measurement. Non-invasive tail-cuff plethysmography is relatively less expensive and
does not require any surgical implantations, but it also does not give precise results.
Investigators have identified the technical factors that most likely affect the accuracy of
tail-cuff measurements while simultaneously recording BP using telemetry. These include
entry of the investigator into the room where the measurements were performed, moving
the cages around, handling the rodent, restraint of the rodent and inflation of the cuff on
the tail. Changes in the BP and heart rate induced by restraint stress and tail-cuff inflation
did not diminish in magnitude, even after many repeated trials. Telemetry on the other hand
is the “gold standard” of BP measurement (Gregory D. Fink, Editorial, AHA, ASA).
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Future experiments
The unexpected drop in BP post-surgery may have prevented the rise of BP in CIH +
SST animals and to avoid any discrepancies in the results, any surgical implantations prior
to BP recordings should be avoided and alternative ways of drug delivery should be
considered. Use of depot injections to avoid unnecessary fluctuations in BP could be used.
Also, the use of CODA non-invasive tail cuff BP measurement system was not the best
choice. Fletcher and his colleagues observed an increase in MAP in rodents exposed to
CIH for 7 h/day for 35 days during their diurnal sleep (Fletcher et al., 1992b)). They placed
indwelling arterial catheter to measure BP. Next time, a greater number of animals and the
use of telemetry for BP recordings can give us better and more accurate results.
Potential Pitfalls
In many studies, Octreotide has been used to treat acromegaly and esophageal variceal
hemorrhage in humans mainly as bolus injections of 50µg followed by 25-50µg/h
(Reynaert et al., 2003). Some also use Long Acting Release (LAR) Octreotide by deep
subcutaneous depot injections to administer a dose of 20mg-40mg/month (Colao et al.,
2009; Tolis et al., 2006). However, to study Long-Term (LT) effects of SST or SSTA, a
dose of 10µg/kg/h or 8mg/kg/month is considered a standard protocol (Schmid et al.,
2012). In the current project, we intended to use 10µg/kg/h of SSTA concentration but due
to wrong calculations we ended up using 8.5µg/kg/h.
With a smaller size in comparison to humans, the basal metabolic rate- the rate of energy
production over a fixed period of time under constant conditions- is much less than that of
man, because of less body mass. However, the mass-specific rate, that is, the basal
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metabolic rate per gram of body weight is known to be seven times greater in rodents than
in humans (Lloyd et al., 2005). As a consequence, it is likely that rats will metabolize
Octreotide drug faster than humans.
Increasing the dose of Octreotide should help mitigate the problems caused by high
metabolic rate and increased rate of drug metabolism. Three conventional concentrations
of drug- 10µg/Kg/h, 30µg/Kg/h and 100µg/Kg/h could be used.
The subtype of SSTRs on the carotid body and carotid sinus nerve are not known but we
do know that the SST analogue Octreotide has high affinity for SSTR2 and SSTR5 and
some affinity for SSTR3 (See Table 1). There is a possibility that the CB/CSN may not
have any SSTR 2, 3 and 5 which means Octreotide would never work. To avoid this, other
SST analogues such as Vapreotide or Somatuline could be tested. They have affinities for
SSTR 2 through 5.
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APPENDIX
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Michael Bottomley
Statistical Programmer Analyst
Statistical Consulting Center
3640 Colonel Glenn Hwy, 130 M&M
Dayton, OH 45435-0001
P: 937-775-2286 F: 937-775-2081
E: michael.bottomley@wright.edu

DATE: 13 February 2018
TO: Kamra, Kajal
FROM: Mike Bottomley
SUBJECT: Final Report for CIH Analysis

Dear Kajal,

Here are the results of the analysis for your chronic intermittent hypoxia (CIH) data. You
are interested in determining if a drug (SST) has any effect on various blood pressure
measures of rats undergoing CIH. You have four treatment groups:
(i)

Normal oxygen conditions and placebo

(ii)

Normal oxygen conditions and SST

(iii)

CIH and placebo

(iv)

CIH and SST

To simulate CIH the rats were placed in a chamber that was intermittently flooded with
nitrogen to lower the oxygen content, and shortly thereafter, the oxygen content was
returned to a regular level. Rats on the drug and rats not on the drug were present in all
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cages. The cages that were not exposed to the CIH conditions had a device that mimics
the sound of the nitrogen blast in order to keep the conditions as similar as possible.
You recorded the systolic blood pressure (SBP), diastolic blood pressure (DBP), and mean
arterial pressure (MAP) of the rats. The rats were measured at the start of the experiment,
after a pump was surgically implanted, and then once a week for four weeks. Five
measurements were taken at each time point. Due to complications arising from the
surgery that implanted the pumps, some of the rats had to be removed from the experiment
before the end of the study. Rats that were removed within a week after the surgery were
excluded from the analysis since the drug would not have had ample time to show an effect.
For each of the three response variables a repeated measures mixed effects ANOVA with
a random effect for rat ID was run. The repeated measures aspect takes the correlation
between time points for each rat into effect and the random effect factors in the correlation
for the 5 measurements on each rat at each of the time points. A level of significance of
alpha = 0.05 was used for each model. Post hoc pairwise comparisons were made via
Tukey’s multiple comparison procedure, which controls for an inflated type I error rate
(rejecting the null hypothesis of no difference when in reality there actually is no
difference) that can arise when multiple comparisons are made. This procedure guarantees
that the experiment-wise type I error rate for each of the three models is at most alpha =
0.05. All analyses were performed on SAS version 9.4. Descriptive statistics for each of
the variables at each time point for each of the treatment groups are given below in Table
1.
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No. of
N
Obs Variable Label N Mean Std Dev Minimum Maximum Miss

Group

Time

CNTRL +
DMSO

Pre

35 SBP
DBP
MAP

SBP
DBP
MAP

3 169.1
5
1
3 129.1
5
1
3 149.2
5
9

23.79
22.28
28.26

107.00
80.00
89.00

210.00
175.00
210.00

0
0
0

Post

35 SBP
DBP
MAP

SBP
DBP
MAP

3 170.8
5
9
3 132.6
5
0
3 144.9
5
4

21.38
19.86
19.02

134.00
108.00
120.00

217.00
180.00
189.00

0
0
0

W1

35 SBP
DBP
MAP

SBP
DBP
MAP

3 148.1
5
1
3 110.1
5
7
3 122.4
5
6

33.21
26.66
28.16

95.00
73.00
84.00

203.00
163.00
176.00

0
0
0

W2

35 SBP
DBP
MAP

SBP
DBP
MAP

3 161.4
5
9
3 121.2
5
3
3 138.4
5
6

20.55
19.49
22.59

135.00
91.00
108.00

214.00
177.00
187.00

0
0
0

W3

35 SBP
DBP
MAP

SBP
DBP
MAP

3 170.8
0
3
3 134.0
0
3
3 145.8
0
7

25.40
25.56
25.07

131.00
90.00
105.00

218.00
192.00
200.00

5
5
5

W4

35 SBP
DBP
MAP

SBP
DBP
MAP

3 170.8
0
7
3 131.3
0
7
3 144.2
0
7

24.07
21.55
20.64

117.00
74.00
96.00

218.00
174.00
188.00

5
5
5

Pre

35 SBP
DBP
MAP

SBP
DBP
MAP

3 151.4
5
9
3 113.4
5
3
3 125.7
5
7

28.81
21.03
23.18

96.00
79.00
84.00

201.00
154.00
166.00

0
0
0

CIH +
DMSO
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Group

CNTRL +
DRUG

Time

No. of
N
Obs Variable Label N Mean Std Dev Minimum Maximum Miss

Post

35 SBP
DBP
MAP

SBP
DBP
MAP

3 156.0
5
9
3 119.4
5
9
3 131.3
5
7

27.40
34.24
30.93

106.00
56.00
73.00

204.00
194.00
197.00

0
0
0

W1

35 SBP
DBP
MAP

SBP
DBP
MAP

3 141.0
5
3
3 105.6
5
3
3 117.0
5
3

37.53
24.33
28.17

70.00
53.00
58.00

191.00
149.00
163.00

0
0
0

W2

35 SBP
DBP
MAP

SBP
DBP
MAP

3 160.8
5
9
3 119.3
5
7
3 132.8
5
3

27.34
19.34
21.27

114.00
86.00
96.00

218.00
154.00
164.00

0
0
0

W3

35 SBP
DBP
MAP

SBP
DBP
MAP

3 156.3
5
1
3 119.0
5
6
3 131.1
5
7

33.68
24.52
27.05

99.00
75.00
85.00

231.00
161.00
184.00

0
0
0

W4

35 SBP
DBP
MAP

SBP
DBP
MAP

2 139.6
5
4
2 110.4
5
8
2 119.9
5
2

27.61
19.40
21.51

84.00
74.00
77.00

178.00
140.00
152.00

10
10
10

Pre

35 SBP
DBP
MAP

SBP
DBP
MAP

3 142.6
5
3
3 106.4
5
0
3 118.1
5
7

33.25
25.13
27.63

94.00
69.00
79.00

197.00
147.00
160.00

0
0
0

Post

35 SBP
DBP
MAP

SBP
DBP
MAP

3 147.0
5
6
3 109.0
5
9
3 121.3
5
4

38.69
27.20
30.25

37.00
32.00
33.00

211.00
170.00
183.00

0
0
0
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Group

CIH +
DRUG

Time

No. of
N
Obs Variable Label N Mean Std Dev Minimum Maximum Miss

W1

35 SBP
DBP
MAP

SBP
DBP
MAP

3 145.6
5
3
3 109.9
5
4
3 121.4
5
6

31.04
24.35
25.85

87.00
66.00
74.00

203.00
180.00
187.00

0
0
0

W2

35 SBP
DBP
MAP

SBP
DBP
MAP

3 150.8
5
0
3 115.2
5
3
3 126.6
5
9

29.80
25.89
26.27

89.00
53.00
79.00

194.00
166.00
174.00

0
0
0

W3

35 SBP
DBP
MAP

SBP
DBP
MAP

3 176.3
5
4
3 136.0
5
0
3 149.2
5
0

22.69
21.77
19.88

137.00
100.00
117.00

222.00
195.00
202.00

0
0
0

W4

35 SBP
DBP
MAP

SBP
DBP
MAP

3 156.6
5
6
3 122.9
5
4
3 133.8
5
3

43.95
37.20
38.96

82.00
61.00
68.00

230.00
181.00
197.00

0
0
0

Pre

25 SBP
DBP
MAP

SBP
DBP
MAP

2 157.6
5
0
2 121.1
5
6
2 133.4
5
0

27.04
27.57
26.94

106.00
67.00
80.00

194.00
162.00
170.00

0
0
0

Post

25 SBP
DBP
MAP

SBP
DBP
MAP

2 162.6
5
8
2 126.6
5
0
2 138.3
5
2

23.31
26.43
24.76

116.00
89.00
98.00

204.00
194.00
197.00

0
0
0

W1

25 SBP
DBP
MAP

SBP
DBP
MAP

2 148.8
5
0
2 108.6
5
0
2 121.6
5
4

32.83
29.36
29.75

104.00
78.00
86.00

237.00
189.00
197.00

0
0
0
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Group

Time

No. of
N
Obs Variable Label N Mean Std Dev Minimum Maximum Miss

W2

25 SBP
DBP
MAP

SBP
DBP
MAP

2 178.2
5
4
2 137.1
5
2
2 150.5
5
6

24.48
18.41
18.71

136.00
112.00
120.00

236.00
188.00
193.00

0
0
0

W3

25 SBP
DBP
MAP

SBP
DBP
MAP

2 165.9
5
6
2 131.1
5
6
2 142.1
5
2

23.15
18.63
19.00

129.00
100.00
109.00

217.00
174.00
183.00

0
0
0

W4

25 SBP
DBP
MAP

SBP
DBP
MAP

2 156.2
5
8
2 124.0
5
8
2 134.4
5
0

29.38
27.29
26.88

90.00
57.00
69.00

204.00
169.00
178.00

0
0
0

Table 1: Descriptive statistics for CIH SST data by treatment group and time

The following three sections detail the results for each of the three response variables. In
each of the three models, presence of a significant interaction between treatment group and
time was detected (P < 0.0001 for each model). This is evidence that any potential
treatment effects are not constant across time. As a result, the time points had to be
compared individually. This resulted in 276 pairwise comparisons being made for each of
the three models that were run. Using a level of alpha = 0.05, with 276 comparisons you
would expect to commit around 14 type I errors by chance, which is why I chose to use
Tukey’s multiple comparison procedure. The interaction is evidenced in the interaction
plots (Figures 1-3) by the non-parallel lines. If the treatment effect were constant across

89

all time points the lines would be approximately parallel and the interaction term would
not be statistically significant.
I.

Systolic Blood Pressure

Of the 276 pairwise comparisons, those that had significant adjusted P-values are given
below in Table 2. Positive estimated mean differences indicate the first value was higher,
negative estimated mean differences indicate the second value was higher. The adjusted
95% confidence intervals give a range of plausible values for the true mean difference.
These intervals appear somewhat wide. This is likely due to the adjustment made to correct
for the multiple comparisons, as well as having a relatively small sample size that displayed
a high amount of variance. The order of subtraction is the same as the order of listing in
the “Comparison” column. The interaction plot follows in Figure 1.

Comparison
CIH + DRUG W1
- CIH + DRUG W2
CNTRL + DMSO
Post - CNTRL +
DMSO W1
CNTRL + DRUG
Post - CNTRL +
DRUG W3
CNTRL + DRUG
Pre - CNTRL +
DRUG W3
CNTRL + DRUG
W1 - CNTRL +
DRUG W3
CNTRL + DRUG
W2 - CNTRL +
DRUG W3

Estimated Mean
Adjusted 95%
Adjusted P-value
Difference
Confidence Interval
-29.44
(-56.99, -1.89)
0.0211
22.77

(1.75, 43.80)

0.0174

-29.29

(-50.66, -7.91)

0.0002

-33.71

(-55.15, -12.28)

< 0.0001

-30.71

(-51.74, -9.69)

< 0.0001

-25.54

(-48.83, -2.26)

0.0144
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Table 2: All significant pairwise comparisons for SBP

Means by Group and Time
SBP
180

170

160

150

140

130
Pre

Post

W1

W2

W3

W4

Time
Group

CNTRL + DMSO

CIH + DMSO

CNTRL + DRUG

CIH + DRUG

Figure 1: Interaction plot for SBP

As we discussed at one of our meetings, some of these results are rather curious.
Descriptively, all of the rats displayed a decrease from Post to W1 (whether or not it was a
statistically significant decrease), which is to be expected while they recover from the
surgery. However, the only rats to show a significant increase from W1 to W2 were the
CIH rats on the SST, which is the opposite of the desired effect. However, it could be
possible that the SST takes time to start working (based on your decision to exclude rats
who were removed before W2. This group did show a descriptive decrease from W2 to
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W3 and from W3 to W4, although not a statistically significant decrease. Perhaps with a
larger sample size and fewer pairwise comparisons this would become statistically
significant. It is also possible that the drug did not have ample time to take full effect and
given more time, this downward trend might have continued (note that this is pure
speculation). I think you mentioned the timeframe of the experiment was limited by the
lifespan of the pump. It is also strange that the control rats on the SST showed significant
increases from Pre to W3, Post to W3, W1 to W3, and W2 to W3. It would seem that this
group would have been the least likely to show any increase in SBP of the three groups if
the SST is effective.

II.

Diastolic Blood Pressure

Comparison

Estimated Mean
Difference

CIH + DRUG W1
- CIH + DRUG W2
CIH + DRUG W1
- CIH + DRUG W3
CNTRL + DMSO
Post - CNTRL +
DMSO W1
CNTRL + DMSO
W1 - CNTRL +
DMSO W3
CNTRL + DRUG
Post - CNTRL +
DRUG W3
CNTRL + DRUG Pre
- CNTRL + DRUG
W3
CNTRL + DRUG W1
- CNTRL + DRUG
W3
CNTRL + DRUG W2
- CNTRL + DRUG
W3

Adjusted 95%
Confidence Interval

Adjusted P-value

-28.52

(-50.80, -6.24)

0.0010

-22.56

(-44.32, -0.80)

0.0321

22.43

(1.22, 43.64)

0.0247

-20.71

(-39.97, -1.45)

0.0196

-26.91

(-48.88, -4.95)

0.0023

-29.60

(-47.63, -11.57)

< 0.001

-26.06

(-44.45, -7.66)

<0.0001

-20.77

(-37.05, -4.49)

0.0010

Table 3: All significant pairwise comparisons for DBP
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Means by Group and Time
DBP
140

130

120

110

100
Pre

Post

W1

W2

W3

W4

Time
Group

CNTRL + DMSO

CIH + DMSO

CNTRL + DRUG

CIH + DRUG

Figure 2: Interaction plot for DBP

All significant pairwise comparisons for SBP were also significant for DBP.

Two

additional pairwise comparisons were also significant. CIH rats on SST had a significantly
higher mean DBP at W3 compared to W1. Control oxygen rats on the placebo had a
significantly higher mean DBP at W3 compared to W1.
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III.

Mean Arterial Pressure

Comparison

Estimated Mean
Adjusted 95%
Adjusted P-value
Difference
Confidence Interval
-28.92
(-52.18, -5.66)
0.0017

CIH + DRUG W1
- CIH + DRUG W2
CNTRL + DMSO
22.49
(1.20, 43.77)
Post - CNTRL +
DMSO W1
CNTRL + DMSO
26.83
(5.72, 47.94)
Pre - CNTRL +
DMSO W1
CNTRL + DRUG
-27.86
(-50.43, -5.29)
Post - CNTRL +
DRUG W3
CNTRL + DRUG
-31.03
(-50.96, -11.10)
Pre - CNTRL +
DRUG W3
CNTRL + DRUG
-27.74
(-46.35, -9.14)
W1 - CNTRL +
DRUG W3
CNTRL + DRUG
-22.51
(-39.00, -6.03)
W2 - CNTRL +
DRUG W3
Table 4: All significant pairwise comparisons for MAP
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0.0250

0.0011

0.0020

< 0.0001

< 0.0001

0.0002

Means by Group and Time
MAP
160

150

140

130

120

110
Pre

Post

W1

W2

W3

W4

Time
Group

CNTRL + DMSO

CIH + DMSO

CNTRL + DRUG

CIH + DRUG

Figure 3: Interaction plot for MAP

MAP shared many of the same pairwise comparisons as SBP and DBP. One that was
different was the mean MAP was significantly higher Pre compared to W1 for the control
oxygen plus placebo group.
Let me know if you have any questions about anything contained in this report.

Sincerely,
Mike Bottomley
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